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We evaluated the disk susceptibility data of 671 nonty-
phoid Salmonella isolates collected from different parts of
Taiwan from March 2001 to August 2001 and 1,261 nonty-
phoid  Salmonella isolates from the National Taiwan
University Hospital from 1996 to 2001. Overall,
ciprofloxacin resistance was found in 2.7% (18/671) of all
nontyphoid  Salmonella isolates, in 1.4% (5/347) of
Salmonella enterica serotype Typhimurium and in 7.5%
(8/107) in S. enterica serotype Choleraesuis nationwide.
MICs of six newer fluoroquinolones were determined for
the following isolates: 37 isolates of ciprofloxacin-resistant
(human) S. Typhimurium (N = 26) and Choleraesuis (N =
11), 10 isolates of ciprofloxacin-susceptible (MIC <1
mg/mL) (human) isolates of these two serotypes, and 15
swine isolates from S. Choleraesuis (N = 13) and
Typhmurium (N = 2) with reduced susceptibility to
ciprofloxacin (MIC >0.12 µg/mL). Sequence analysis of the
gryA,  gyrB,  parC,  parE, and acrR genes, ciprofloxacin
accumulation, and genotypes generated by pulsed-field gel
electrophoresis with three restriction enzymes (SpeI, XbaI,
and BlnI) were performed. All 26 S. Typhimurium isolates
from humans and pigs belonged to genotype I. For S.
Choleraesuis isolates, 91% (10/11) of human isolates and
54% (7/13) of swine isolates belonged to genotype B.
These two genotypes isolates from humans all exhibited a
high-level of resistance to ciprofloxacin (MIC 16–64
mg/mL). They had two-base substitutions in the gyrA gene
at codons 83 (Ser83Phe) and 87 (Asp87Gly or Asp87Asn)
and in the parC gene at codon 80 (Ser80Arg, Ser80Ile, or
Ser84Lys). Our investigation documented that not only did
these two S. enterica isolates have a high prevalence of
ciprofloxacin resistance nationwide but also that some
closely related ciprofloxacin-resistant strains are dissemi-
nated from pigs to humans.
I
nfections caused by nontyphoid Salmonella in humans
are increasingly frequent in developed and developing
countries (1,2). The increasing rates of resistance to tradi-
tional anti-Salmonella agents (i.e., ampicillin, chloram-
phenicol, and trimethoprim-sulfamethoxazole) and
extended-spectrum cephalosporins among these isolates
have made treatment of invasive salmonellosis a clinical
dilemma (3–6). Of particular concern is the emergence of
fluoroquinolone resistance among nontyphoid Salmonella
and the occurrence of outbreaks caused by some resistant
clones, since this class of antimicrobial agents constitutes
the drug of choice for treating potentially life-threatening
Salmonella infections caused by the multidrug-resistant
strains in adult persons (7–16). Moreover, cases of treat-
ment failure due to fluoroquinolone resistance in
Salmonella strains have been reported (17–19). 
Researchers have increasingly reported that widespread
use of fluoroquinolones in food animals leads to the rapid
emergence and dissemination of resistant Salmonella
infections to humans, particularly in developing countries
(4,8,20–23). In Taiwan, Chiu et al. reported that resistance
to ciprofloxacin among S. enterica Choleraesuis isolates
first appeared in 2000 and <60% of the isolates recovered
from two hospitals in northern Taiwan in the third quarter
of 2001 were resistant to ciprofloxacin (14). Molecular
investigation clearly demonstrated that the primary
sources of these resistant strains were herds of pigs.
To better understand the prevalence of nationwide
resistance and the probable dissemination of
ciprofloxacin-resistant nontyphoid Salmonella isolates,
particularly S. Typhimurium and Choleraesuis, we deter-
mined the mechanisms of quinolone resistance and the
genotypes of ciprofloxacin-resistant isolates from humans
and pigs, collected in different parts of Taiwan. This study
is part of the Surveillance from Multicenter Antimicrobial
RESEARCH
Ciprofloxacin-resistant 
Salmonella enterica Typhimurium
and Choleraesuis from Pigs to
Humans, Taiwan 
Po-Ren Hsueh,*† Lee-Jene Teng,*† Sung-Pin Tseng,* Chao-Fu Chang,‡ Jen-Hsien Wan,† 
Jing-Jou Yan,† Chun-Ming Lee,† Yin-Ching Chuang,† Wen-Kuei Huang,† Dine Yang,† 
Jainn-Ming Shyr,† Kwok-Woon Yu,† Li-Shin Wang,† Jang-Jih Lu,† Wen-Chien Ko,† Jiunn-Jong Wu,†
Feng-Yee Chang,† Yi-Chueh Yang,† Yeu-Jun Lau,† Yung-Ching Liu,† Cheng-Yi Liu,† 
Shen-Wu Ho,† and Kwen-Tay Luh*†
60 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004
*National Taiwan University College of Medicine, Taipei, Taiwan;
†The Study Group of Surveillance from Multicenter Antimicrobial
Resistance in Taiwan, Taipei, Taiwan; and ‡Graduate Institute of
Veterinary Medicine, National Taiwan University, Taipei, Taiwan Resistance in Taiwan (SMART) programs conducted in
2001.
Materials and Methods
Bacterial Isolates 
A total of 671 nontyphoid Salmonella isolates were col-
lected for the study. These isolates were recovered from
various clinical specimens of patients treated at 11 major
hospitals (bed capacities from 800 to 2,000) in different
regions of Taiwan. These hospitals included the National
Taiwan University Hospital (NTU; hospital A), Taipei;
Taipei Veterans General Hospital (hospital B), Taipei;
Mackay Memorial Hospital (hospital C), Taipei; Tri-service
General Hospital (hospital D), Taipei; Taichung Veterans
General Hospital (hospital E), Taichung; China Medical
College Hospital (hospital F), Taichung; National Cheng-
Kung University Hospital (hospital G), Tainan; Chi-Mei
Medical Center (hospital H), Tainan; Kaohsiung Veterans
General Hospital (hospital I), Kaohsiung; and Tzu-Chi
General Hospital, Hualien (hospital J). Of the 671 isolates
tested, 429 (64%) were recovered from stool samples, 141
(21%) from blood, and the rest from various body fluids. 
Disk diffusion susceptibility results on these isolates
were also provided by the hospitals and evaluated.
Organisms were categorized as susceptible or resistant
(including intermediate isolates) to the antimicrobial
agents tested on the basis of  the guidelines provided by the
National Committee for Clinical Laboratory Standards
(NCCLS) (24). Isolates of Salmonella serogroups B and C
were further identified to the serotype level, according to
the Kauffman and White scheme, by using somatic and fla-
gellar antigens (Denka Seiken Co., Ltd., Tokyo, Japan) and
also by conventional methods and the Phoenix System
(panel type, NMIC/ID4) (Becton Dickson, Sparks, MD) at
hospital A (25). Table 1 shows the number of isolates of
nontyphoid  Salmonella,  S.  Typhimurium, and S.
Choleraesuis, and the ciprofloxacin resistance for the two
serotypes of S. enterica isolates recovered from the 11 hos-
pitals. 
Atotal of 13 isolates of S. Choleraesuis and two isolates
of S. Typhimurium recovered from pigs raised in southern
(N = 11) and central (N = 4) Taiwan from 1997 to 2002
were also collected for study. Of the 15 isolates, 2 each
were collected in 1997, 1999, and 2001 and 3 each in 1998,
2000, and 2002. These isolates were collected from vari-
ous visceral organs (lungs, liver, or spleen) or from stool
specimens of pigs that died of septicemia. All the isolates
were stored at –70°C in trypticase soy broth (Difco
Laboratories, Detroit, MI) supplemented with 15% glyc-
erol before being further tested. S.  Choleraesuis ATCC
13312 and S.  Typhimurium ATCC 14028 were used as
control strains.
Prevalence of Resistance at Hospital A
To determine the prevalence of antimicrobial resistance
among nontyphoid Salmonella, we analyzed the disk diffu-
sion susceptibility results of these organisms to ampicillin,
cefotaxime/ceftriaxone, chloramphenicol, trimethoprim-
sulfamethoxazole, and ciprofloxacin recovered from 1996
to 2001 at hospital A. Isolates of Salmonella serogroups B
and C resistant to ciprofloxacin (by the disk diffusion
method) were further identified to the serotype level by the
methods mentioned above.
Antimicrobial Susceptibility Testing
Of the 671 isolates collected from 11 medical centers in
2001, 37 ciprofloxacin-resistant (by the disk diffusion
method) S. Typhimurium (N = 26) and S. Choleraesuis (N
= 11) isolates and 10 randomly selected ciprofloxacin-sus-
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Table 1. Number of ciprofloxacin-resistant nontyphoid Salmonella, S. enterica Typhimurium, and S. enterica Choleraesuis isolates from 
patients treated at 11 major teaching hospitals in different regions of Taiwan, March 2001–August 2001 
% (no. ciprofloxacin-resistant isolates/no. total isolates) of 
ciprofloxacin-resistant isolates, by serotype 
Hospital 
% (no. ciprofloxacin-resistant isolates/no. total isolates) of 
ciprofloxacin-resistant isolates of total nontyphoid Salmonella  Typhimurium  Choleraesuis  Others 
Northern region  4.3 (7/231)  3.5 (3/85)  7.7 (2/26)  1.7 (2/120) 
A  0.0 (0/100)  0.0 (0/40)  0.0 (0/13)  0.0 (0/47) 
B  8.2 (4/49)  0.0 (0/19)  28.5 (2/7)  8.7 (2/23) 
C  1.7 (1/60)  5.6 (1/18)  0.0 (0/3)  0.0 (0/39) 
D  9.1 (2/22)  25.0 (2/8)  0.0 (0/3)  0.0 (0/11) 
Central region  3.9 (6/154)  2.4 (2/85)  6.1 (2/33)  5.6 (2/36) 
E  5.3 (3/57)  2.8 (1/36)  7.1 (1/7)  7.1 (1/14) 
F  7.7 (3/97)  2.0 (1/49)  3.8 (1/26)  4.5 (1/22) 
Southern region  2.0 (5/255)  0.0 (0/155)  9.5 (4/42)  1.7 (1/58) 
G  0.0 (0/99)  0.0 (0/67)  0.0 (0/11)  0.0 (0/21) 
H  2.3 (2/86)  0.0 (0/55)  11.8 (2/17)  0.0 (0/14) 
I  4.3 (3/70)  0.0 (0/33)  14.3 (2/14)  4.3 (1/23) 
Eastern region         
J  0.0 (0/31)  0.0 (0/22)  0.0 (0/6)  0.0 (0/3) 
Total  2.7 (18/671)  1.4 (5/347)  7.5 (8/107)  2.3 (5/217) ceptible (by the disk diffusion method) isolates of these
two serotypes were tested for susceptibility to six fluoro-
quinolones (ciprofloxacin, levofloxacin, moxifloxacin,
trovafloxacin, gatifloxacin, and garenoxacin) to determine
their MICs by using the agar dilution method according to
the guidelines established by  NCCLS (26). The 37
ciprofloxacin-resistant isolates included 13 isolates from
the 2001 SMART program (5 S. Typhimurium isolates and
8 S. Choleraesuis isolates) and 24 recovered from 1996 to
2000 at hospital A (21 S. Typhimurium isolates and 3 S.
Choleraesuis isolates). These ciprofloxacin-resistant iso-
lates were recovered from 29 patients. Six patients
(patients 9, 10, 11, 15, 29, and 32) had isolates that were
recovered after >7 days from various clinical specimens.
The patients’ ages ranged from <1 year to 84 years (mean
31 years); those <2 years of age were predominant (47%)
among patients with S. Typhimurium isolations. None of
the patients with S.  Choleraesuis bacteremia were <16
years. Among the 37 human isolates of ciprofloxacin-
resistant nontyphoid Salmonella isolates, 13 (3 of S.
Typhimurium and 10 of S. Choleraesuis) were recovered
from blood specimens of 12 patients with bloodstream
infections. The rest of the isolates were recovered from
stool or urine specimens.
Dilution susceptibilities to the aforementioned fluoro-
quinolones were also performed for the 15 isolates from
pig herds, according to the NCCLS guidelines (26). 
PCR Amplification and DNA Sequencing of 
gyrA, gyrB, parC, parE, and acrR
The sequences of the primers for the polyermase chain
reaction (PCR) amplification of gryA, gyrB, parC, parE,
and  acrR have been previously described (27–30). The
preparation of the template DNA and the determination of
sequences of each gene followed the procedures described
previously (27–29). The sequences of the quinolone resist-
ance-determining regions (QRDRs) were determined to be
between amino acids 54 and 171 of gyrA, 397 and 520 of
gyrB, 12 and 130 of parC, and 421 and 524 of parE.  
Ciprofloxacin Accumulation 
The accumulation of ciprofloxacin, with or without 100
mM carbonyl cyanide m-chlorophenylhydrazone, was
determined for two ciprofloxacin-resistant strains and one
ciprofloxacin-susceptible S. Typhimurium (ciprofloxacin
MIC = 0.06 µg/mL) as described previously (28,29).
These experiments were performed twice to ensure repro-
ducibility.
Molecular Typing
Genotyping of the human ciprofloxacin-resistant S.
Typhimurium (N = 26) and Choleraesuis (N = 11) isolates,
the 10 human ciprofloxacin-susceptible isolates of the two
serotypes, and the 15 isolates from pigs was determined by
the pulsotypes generated by pulsed-field gel electrophore-
sis (PFGE). The DNA extraction and purification were
also carried out as described previously (31,32). The DNA
was digested by the restriction enzymes SpeI, XbaI, and
BlnI (9,16,23,32), and the restriction fragments were sep-
arated in a CHEF-DRIII unit (Bio-Rad, Hercules, CA).
Interpretation of the PFGE profiles followed the descrip-
tion by Tenover et al. (33). Isolates belonging to the simi-
lar pulsotypes (within six band differences) by each of the
three restriction enzymes were defined as the same geno-
types (closely related clusters). Isolates with identical pul-
sosubtypes (no band differences) by the three restriction
enzymes were defined as the same genosubtypes (clones).
Results
Nationwide Resistance in 2001
The rates of ciprofloxacin resistance among isolates of
nontyphoid  Salmonella,  S.  Typhimurium, and S.
Choleraesuis from the 11 hospitals, stratified by region of
Taiwan, is shown in Table 1. Overall, ciprofloxacin resist-
ance was found in 2.7% (18/671) of all nontyphoid
Salmonella isolates from humans, 1.4% in S. Typhimurium
and 7.5% in S. Choleraesuis nationwide (Table 1). Among
S. Choleraesuis isolates, the highest rate of ciprofloxacin
resistance was found in hospital B (28.5%) and southern
region of Taiwan (9.5%). Among S. Typhimurium isolates,
the highest rate of ciprofloxacin resistance was found in
hospital D (25.0%) and in the northern region of Taiwan
(3.5%). Nontyphoid Salmonella isolates recovered from
patients in eastern region of Taiwan were all susceptible to
ciprofloxacin. Rates of resistance to ampicillin and chlo-
ramphenicol were higher in eastern Taiwan than those
from other regions of Taiwan. Resistance to cefotaxime
(three hospitals tested ceftriaxone instead of cefotaxime)
among all nontyphoid Salmonella isolates was low (<1%).
However, 6% and 4% of S. Choleraesuis isolates recovered
from central and southern Taiwan, respectively, were
resistant to cefotaxime (ceftriaxone). 
Prevalence of Ciprofloxacin Resistance at Hospital A
The annual number of nontyphoid Salmonella isolates
(Salmonella group B and Salmonella  group C) ranged
from 294 in 1996 (182 and 46, respectively) to 90 in 2001
(76 and 8, respectively). Overall, the rate of ciprofloxacin
resistance among nontyphoid Salmonella isolates was
2.1%. For Salmonella group B isolates, the rates of
ciprofloxacin resistance were high (6% to 9%) during 1996
and 1997, reached a trough in 1999 (3%), and increased
gradually in the following 2 years (4% in 2000 to 5% in
2001). Annual rates of resistance to ciprofloxacin among
Salmonella group C isolates fluctuated during the same 6-
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none of the isolates were resistant to ciprofloxacin, and the
highest rate of ciprofloxacin resistance was found in 2000
(13%).
The annual rates of resistance to ampicillin, cefotaxime,
chloramphenicol, and trimethoprim-sulfamethoxazole
among all nontyphoid Salmonella isolates,  Salmonella
group B, and Salmonella group C at hospital A from 1996
to 2001 were evaluated. Overall, the prevalence of resist-
ance to cefotaxime among these isolates was low (0% to
4%). Rates of resistance to ampicillin, chloramphenicol,
and trimethoprim-sulfamethoxazole among all nontyphoid
Salmonella isolates declined gradually from 1996 (64%,
64%, and 42%, respectively) to 2000 (47%, 52%, and
34%, respectively). In 2001, however, rates of resistance to
ampicillin (73%) and chloramphenicol (76%) increased
but that of trimethoprim-sulfamethoxazole (28%) contin-
ued to decrease. A similar scenario was found among
Salmonella group B isolates. For Salmonella group C iso-
lates, rates of resistance to these agents also fluctuated dur-
ing the study period. 
Antimicrobial Susceptibilities of Human 
Ciprofloxacin-resistant Isolates
All of the human ciprofloxacin-resistant isolates were
highly resistant to ampicillin (MIC >128 µg/mL), chloram-
phenicol (MIC >128  µg/mL), and trimethoprim-sul-
famethoxazole (>128 µg/mL) but susceptible to cefotaxime
(MIC 0.06–8 µg/mL). These ciprofloxacin-resistant iso-
lates from humans all exhibited high-levels of resistance to
ciprofloxacin (MIC 8 to 64 µg/mL), levofloxacin (MIC
32–64 µg/mL), moxifloxacin (MIC 32–28 µg/mL), gati-
floxacin (MIC 16–32 µg/mL), garenoxacin (MIC 16–64
µg/mL), and trovafloxacin (MIC 8–64 µg/mL). 
Fluoroquinolone Susceptibilities among 
Swine S. Choleraesuis Isolates 
All 15 isolates of S. Typhimurium and Choleraesuis
from pigs had reduced susceptibility to ciprofloxacin
(MIC >0.125 µg/mL). Eight of the 15 isolates (53%) were
susceptible or intermediate to ciprofloxacin according to
the NCCLS breakpoint recommendation (MIC <2
µg/mL). Seven (47%) isolates had high ciprofloxacin
MICs (MIC >64 µg/mL); these seven isolates were also
highly resistant to five other newer fluoroquinolones: lev-
ofloxacin (MIC 32–64 µg/mL), moxifloxacin (MIC
32–128  µg/mL), trovafloxacin (MIC 64 µg/mL), gati-
floxacin (MIC 16–32 µg/mL), and garenoxacin (MIC
32–64 µg/mL). 
Nucleotide Sequence Analysis
Of human ciprofloxacin-resistant S. Typhimurium iso-
lates, all were associated with two-base substitutions in the
QRDR of gyrA at codon 83 (Ser83Phe) (TCC→TTC) and
87 (Asp87Gly) (GAC→GGC), and either Ser80Arg or
Glu84Lys in the QRDR of the parC gene (Table 2). One
base substitution in the QRDR of gyrA (Ser83Tyr or
Ser83Phe) was found in ciprofloxacin-susceptible isolates.
One isolate had a mutation in the QRDR of the gyrB gene,
but none had mutations in the QRDR of the parE gene.
None of the S.  Typhimurium isolates, including
ciprofloxacin-susceptible or -resistant isolates, had muta-
tions in the acrR genes.
Of human ciprofloxacin-resistant S. Choleraesuis, all
were associated with two-base substitutions in the QRDR
of the gyrA gene at codon 83 (Ser83Phe) and 87
(Asp87Asn), Ser80Ile in the QRDR of the parC gene, and
Gln78Stp in the QRDR of the acrR gene (Table 3). None
of these isolates had mutations in the QRDR of the gyrB or
parE genes. One base substitution in the QRDR of the
RESEARCH
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 1, January 2004 63
Table 2. Characteristics of Salmonella enterica serotype Typhimurium isolates from humans
a and pigs,
b Taiwan 
Mutation at 
gyrA gene  parC gene  acrR gene 
Ciprofloxacin 
susceptibility (N) 
MIC 
(µg/mL) 
Ser83Phe 
Asp87Gly 
(N) 
Ser83Phe 
Asp87Asn 
(N) 
Ser83Phe 
(N) 
Ser83Tyr 
(N) 
Ser80Arg 
(N) 
Glu84Lys 
(N) 
Gln78Stp 
(N) 
Arg107Cys 
(N) 
Genotype: 
genosubtype 
Humans 
Resistant (26)  16-64  24  2  0  0  24  2  0  0  I (26), Ia (4), 
Ic (5), Id (6), 
Ie (1), If (1), 
Ig (2), Ih (1), 
Ii (1) Ij (1), Ik 
(2), Il (1) 
Susceptible (5)  0.03-0.25  0  0  1  2  0  0  0  0  IIa (1), IIb (1), 
III (1), IV (1), 
V (1) 
Pigs                       
Resistant (2)  128  2  0  0  0  2  0  0  0  I (2): Ic (1), 
Im (1) 
aN = 31. 
bN = 2. gyrA (Asp87Asn) was found in the ciprofloxacin-suscepti-
ble isolates.
Of pig herd ciprofloxacin-resistant S. Typhimurium iso-
lates (N = 2), both had a mutation in the QRDR of the gyrA
and parC genes, respectively (Table 2). None of these iso-
lates had mutations in the QRDR of the gyrB, parE, or arcR
genes. Among pig herd ciprofloxacin-resistant S.
Choleraesuis isolates, all had two mutations in the QRDR
of gyrA (Ser83Phe plus Asp87Asn or Asp87Gly) and one
mutation in parC (Ser80Ile) and arcR (Gln78Stp) (Table 3). 
PFGE Analysis and Genotypes
All of the ciprofloxacin-resistant S. Typhimurium iso-
lates from humans had the same pulsotype (pulsotype S)
when the SpeI restriction enzyme was used. Figures 1 and
2 illustrate the pulsotypes and pulsosubtypes of S.
Typhimurium (Figures 1A and 1B) and S. Choleraesuis
(Figures 2A, 2B, and 2C) isolates by XbaI and BlnI. Using
XbaI and BlnI, we observed six and eight pulsosubtypes,
respectively,  for S.  Typhimurium isolates. Among S.
Choleraesuis isolates, one pulsotype (x) and one pulsosub-
type (x-1) were observed when the XbaI restriction
enzyme was used, and two pulsotypes (a and b) with six
pulsosubtypes (b-1 to b-6) were observed when the BlnI
restriction enzyme was used. Using the three restriction
enzymes, we found that all ciprofloxacin-susceptible iso-
lates of S. Typhimurium and Choleraesuis had different
genosubtypes (clones).
Among human ciprofloxacin-resistant S. Typhimurium
isolates, all were closely related (genotype I) and belonged
to 11 genosubtypes (genosubtypes Ia to Ik). Among the 11
genosubtypes, Ia (4 isolates), Ic (5 isolates), and Id (6 iso-
lates) predominated. The five ciprofloxacin-susceptible
isolates belonged to four genotypes (II–V) (Table 2). None
of the genotypes among the S. Typhimurium isolates stud-
ied were identical to those of DT104.
Of human S. Choleraesuis isolates, 91% (10 of the 11
isolates) belonged to genotype B, which was different from
those of the five ciprofloxacin-susceptible isolates from
humans (genotypes C to G). None of the six genosubtypes
(B1 to B6) of the genotype B isolates was predominant.
Two isolates collected within 7 days of one another from
patient 4 had identical genosubtypes (B2), but those from
patient 7 had differing genosubtypes (B4 and B5) (Table 3). 
Seven (54%) of the 13 swine S. Choleraesuis isolates
belonged to genotype B (Table 3). Among the six genosub-
types of genotype B, two genosubtypes (B2 and B5) were
also found in human isolates. Two swine isolates that
showed descreased susceptibility to ciprofloxacin (MICs,
0.5 µg/mL and 2 µg/mL, respectively) also belonged to
genotype B (genosubtypes B7 and B10, respectively). 
Evidence for Active Efflux
Ciprofloxacin uptake appeared to be remarkably low in
the two ciprofloxacin-resistant genotypes (genosubtypes Ia
and B1) (Figure 3). A rapid increase in cell-associated
ciprofloxacin uptake among isolates belonging to the
genosubtypes was evident after addition of carbonyl
cyanide m-chlorophenylhydrazone (CCCP), a proton
motive force uncoupler. 
Discussion
This report describes the rates of antimicrobial resist-
ance among nontyphoid Salmonella isolates in a universi-
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Table 3. Characteristics of Salmonella enterica serotype Choleraesuis isolates from humans
a and pigs
b in Taiwan 
Mutation at 
gyrA gene  parC gene  acrR gene 
Ciprofloxacin 
susceptibility (N) 
MIC 
(µg/mL) 
Ser83Phe 
Asp87Asn 
(N) 
Ser83Phe 
(N) 
Asp87Asn 
(N) 
Ser83Tyr 
(N) 
Asp87Gyr 
(N) 
Ser80Ile 
(N) 
Gln78Stp 
(N) 
Arg107Cys 
(N) 
Genotype: 
genosubtype (N) 
Humans                     
Resistant (11)  16–64  11  0  0  0  0  0  0  0  A (1); B (10): B1 
(2), B2 (2), B3 
(2), B4 (1), B5 
(2), B6 (1) 
                     
Susceptible (5) 
 
0.03–0.25  0  0  1  0  0  0  0  0  C (1), D (1), E 
(1), F (1), G (1) 
Pigs 
 
                   
Resistant (5) 
 
64  5  5  0  0  0  5  5  0  0 B (5): B2 (1), 
B5 (1), B8 (1), 
B9 (2) 
Susceptible or 
intermediate (8) 
0.5–2  0  1  1  2  4  0  0  0  B (2): B7 (1), 
B10 (1); H (1), I 
(1), J (3), K (1) 
aN = 16. 
bN = 13. ty hospital during a 6-year period. Furthermore, it charac-
terizes the nationwide dissemination of ciprofloxacin-
resistant strains of S. Typhimurium and Choleraesuis. Our
observations in Taiwan suggest five important facets: First,
ciprofloxacin resistance among our nontyphoid
Salmonella from humans was high (2.7%), particularly
among human S. Choleraesuis isolates. Furthermore, a pre-
vious study found a remarkably high incidence (57%, 12
of 21 isolates) of S. Choleraesuis at two major teaching
hospitals in northern Taiwan in the second to third quarters
of 2001 (14). This observation contrasts greatly with our
findings (7.7%, 2 of 25 isolates, from four hospitals in
northern Taiwan, or 7.5% nationwide from March 2001 to
August 2001) (14).
Second, nearly all ciprofloxacin-resistant S.
Choleraesuis isolates from humans and pigs collected in
1999–2002 were closely related to one another (genotype
B) and differed from those found in pigs in 1997–1998
(these isolates had highly diverse genotypes). These find-
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Figure 1. Pulsotypes and pulsosubtypes of S. enterica serotype
Typhimurium from humans and pigs obtained by pulsed-field gel
electrophoresis (PFGE) after digestion with XbaI (A) and BlnI. (B).
Lanes M, molecular size marker. See Tables 2 and 3 for the des-
ignation of isolates for each indicated pulsotype or pulsosubtype. 
Figure 2. Pulsotypes and pulsosubtypes of Salmonella enterica
serotype Choleraesuis from humans and pigs obtained by pulsed-
field gel electrophoresis (PFGE) after digestion with XbaI (A) and
BlnI (B and C). Lanes M, molecular size marker. See Tables 2 and
3 for the designation of isolates for each indicated pulsotype or
pulsosubtype.ings suggest that nationwide dissemination of S.
Choleraesuis isolates from pigs to humans occurred from
1999 to 2002. Two isolates (AC-6 and AC-10) of S.
Choleraesuis from pigs had reduced susceptibility to
ciprofloxacin (MICs, 0.5 µg/mL and 2 µg/mL, respective-
ly). They had an identical genotype (genotype B) to that of
most of the epidemic strains found in humans and pigs.
These strains had high-level ciprofloxacin resistance (MIC
16 to 64 µg/mL). This indicates that the swine isolates with
reduced susceptibility to ciprofloxacin might be an ances-
tor (a unique clone line) of the isolates that are highly
resistant to ciprofloxacin and which have spread among
herbs and humans nationwide (23,27). 
Third, the S.  Typhimurium strains (genotype I) with
high-level fluoroquinolone resistance have been widely
disseminated in humans in Taiwan since 1996. Strains
belonging to genotype I and the other genotypes found in
this study were domestically acquired and were not related
to the clones of DT104, which were already disseminated
throughout Europe  and the United States (15,23). In 1998,
one isolate exhibiting genotype I (genosubtype Ic) was iso-
lated from a pig from southern Taiwan. Further studies on
S. Typhimurium isolates from animals should be conduct-
ed to identify the primary source of the epidemic genotype
strains. 
Fourth, an increasing prevalence of resistance to ampi-
cillin and chloramphenicol over time was observed in
human S. Typhimurium isolates at hospital A. The spread
of third-generation cephalosporin-resistant isolates harbor-
ing plasmid-mediated CMY-2 like cephalosporinase
among  S.  Typhimurium isolates has been previously
reported in Taiwan (6). Although all of the highly
ciprofloxacin-resistant isolates in our study were suscepti-
ble to cefotaxime, according to NCCLS guidelines (24),
five isolates from four patients with high cefotaxime MICs
(MIC 4–8 µg/mL) is noteworthy. The emergence of
decreased susceptibility to cefotaxime, along with the pre-
existing ciprofloxacin resistance among nontyphoid
Salmonella isolates, particularly those causing blood-
stream infection, makes antimicrobial therapy more com-
plicated.
Finally, rates of resistance varied geographically; high-
er rates of resistance to ampicillin and chloramphenicol
were found in the eastern region of Taiwan. However, none
of the nontyphoid Salmonella isolates collected in the east-
ern region of Taiwan was resistant to ciprofloxacin. 
S. Typhimurium and S. Choleraesuis isolates with high
levels of resistance to ampicillin, chloramphenicol,
trimethoprim-sulfamethoxazole, cipro-floxacin, and other
newer fluoroquinolones were rarely previously reported
(2,19,28,30,34). In most gram-negative bacteria, including
Salmonella, a high-level of fluoroquinolone resistance is
related to the presence of multiple mutations in the QRDRs
of the genes, particularly in the gyrA and  parC  genes
(8,13,14,19,27,28,35). 
Additional resistance mechanisms, such as decreased
cell envelope permeability (loss of outer membrane porins
or alterations of the lipopolysaccharide), decreased cellular
accumulation of quinolones involving the major multidrug
active efflux pump (AcrAB), or the presence of integrons,
can also be responsible for fluoroquinolones resistance and
resistance to a wide range of antimicrobial agents
(31,35–39). Mutations in the acrR (regulator/repressor)
gene are partly responsible for fluoroquinolone resistance
in Escherichia coli (29). In our study, the two major geno-
types (genotypes I and B) of ciprofloxacin-resistant iso-
lates had both mutations in the gyrA (at least two muta-
tions) and parC (at least one mutation) genes. The addition
of CCCP, resulted in an increase in cell-associated
ciprofloxacin uptake. This indicated that an active efflux
contributed to fluoroquinolone resistance (28–31). In our
study, acrR mutations were found in ciprofloxacin-resist-
ant S. Choleraesuis, but not in Typhimurium, isolates. This
finding is consistent with that of previous reports (30).
Further studies are warranted to add clarification to the
complexity of the mechanisms of high-level resistance
among S. Typhimurium and Choleraesuis isolates.
PFGE analysis using restriction enzyme XbaI is a well-
established method for epidemiologic typing of the
Salmonella species (9,16,23,32). However, PFGE patterns
by XbaI for most ciprofloxacin-resistant isolates investi-
gated, including S. Choleraesuis isolates from human and
animal origins, were indistinguishable. This scenario was
also found in PFGE patterns for human S. Typhimurium
isolates. When BlnI was added, the discriminatory power
of pulsotyping improved among these ciprofloxacin-resist-
ant isolates. Genotyping by using pulsotypes generated by
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Figure 3. Accumulation of ciprofloxacin by the two ciprofloxacin-
resistant isolates of genosubtype Ia of Salmonella Typhimurium
and genosubtype B1 of S. Choleraesuis and one clinical isolate of
S.  Typhimurium (ciprofloxacin MIC = 0.06 µg/mL). Carbonyl
cyanide m-chlorophenylhydrazone (CCCP) (100 µM) was added
at the time indicated by the arrow. XbaI and BlnI clearly demonstrated that several
ciprofloxacin-resistant clones (particularly, genosubtypes
Ia, Ic, and Id of S.  Typhimurium) had disseminated to
humans in Taiwan. Furthermore, some genosubtypes of
ciprofloxacin-resistant S. Choleraesuis were found only in
humans, and some were found only in pigs; however, two
clones (genosubtypes B2 and B5) were found in both
humans and pigs. 
Research studies have provided evidence that antimi-
crobial agents used in agriculture and closely related
agents used in human medicine have been exerting selec-
tive pressure on their target bacteria, particularly
Salmonella,  Campylobacter, and Escherichia coli
(1,20,40). In Taiwan, quinolones (e.g., enrofloxacin) have
been used in animals and humans (from nalidixic acid to
the latest fluoroquinolone moxifloxacin) for >30 years. A
governmental survey among farmers and feed mill opera-
tors in 1999 indicated that 40% of farmers and 50% of feed
mill operators used quinolone agents (particularly
enrofloxacin) on their flocks or herds of pigs for growth
promotion or therapeutic purposes (41). Previous investi-
gations demonstrated that >90% of Campylobacter species
and 6% of E. coli from chickens were resistant to
ciprofloxacin (41,42). When the selective pressure of
quinolones persisted, isolates, or some clones with reduced
susceptibility (a single gyrA mutation) to quinolones,
might develop full resistance (two gyrA mutations or mul-
tiple mutations in the QRDRs of other genes) in animals or
humans and could probably jump from animals to humans
(14,27). Our observations and findings from Chiu et al.
indicate that outbreak-associated human Salmonella
strains with high-level ciprofloxacin resistance might have
emerged several years ago, similar to strains with antibio-
types of reduced susceptibility, but with identical geno-
types, in humans or animals (14).
In conclusion, our investigation documented that S.
Typhimurium and S. Choloraesuis isolates, which are high-
ly fluoroquinolone-resistant and multidrug-resistant, have
become widespread pathogens in Taiwan. The recent
occurrence of ciprofloxacin resistance among Salmonella
in animals, and its nationwide spread, is of particular con-
cern. The remaining therapeutic options available to vet-
erinarians and physicians for treatment of extraintestinal
salmonellosis and other invasive infections include only
third-generation cephalosporins. However, ciprofloxacin-
resistant isolates, with reduced susceptibility to cefo-
taxime, have already emerged in Taiwan. Restricted use of
quinolones in animal husbandry and active surveillance of
quinolone resistance among Salmonella are crucial mitiga-
tion efforts to reduce selection and clonal spread of
quinolone-resistant Salmonella.  
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